Smad8 Inhibitors
Smad8 inhibitors are a class of chemical compounds that specifically target and block the activity of Smad8, a member of the Smad family of proteins that play critical roles in the signaling pathways initiated by transforming growth factor-beta (TGF-β) superfamily ligands. Smad8, along with Smad1 and Smad5, is primarily involved in the bone morphogenetic protein (BMP) signaling pathway, which regulates various cellular processes such as differentiation, proliferation, and apoptosis. Upon activation by BMP receptors, Smad8 becomes phosphorylated, allowing it to form complexes with other Smad proteins, which then translocate to the nucleus to regulate the transcription of target genes. Inhibitors of Smad8 function by preventing its phosphorylation or disrupting its ability to interact with other Smads and DNA, thereby blocking its downstream signaling effects.
The use of Smad8 inhibitors in research offers important insights into the precise regulation of BMP signaling and the broader cellular processes governed by this pathway. By inhibiting Smad8, researchers can explore how the loss of Smad-mediated transcriptional activity affects cellular behaviors such as growth, differentiation, and response to environmental signals. This can help clarify the specific contributions of Smad8 in relation to other Smads like Smad1 and Smad5, which have overlapping roles in BMP signaling but may regulate distinct gene sets. Furthermore, studying Smad8 inhibition provides a valuable tool for dissecting the complex cross-talk between different signaling pathways, including how BMP signaling integrates with other regulatory networks to control cell fate decisions. Through such research, Smad8 inhibitors contribute to a deeper understanding of the molecular mechanisms that underlie cellular responses to growth factors and how these processes are tightly coordinated to maintain cellular homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is a selective inhibitor of the TGF-β type I receptor, also known as activin receptor-like kinase 5 (ALK5). Its inhibition of ALK5 impacts the TGF-β signaling pathway, which may indirectly influence Smad8 activity. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $105.00 $153.00 | 4 | |
LY364947 is another selective inhibitor of ALK5, exerting its effects by blocking the TGF-β type I receptor. By inhibiting ALK5, LY364947 interferes with the canonical TGF-β signaling pathway, which may impact Smad8 activity indirectly. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $198.00 $650.00 | 16 | |
A83-01 is a small molecule inhibitor that targets ALK5, similar to SB431542 and LY364947. Through its interaction with ALK5, A83-01 hinders the phosphorylation and activation of the TGF-β type I receptor, potentially modulating downstream Smad8 signaling indirectly. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $75.00 $150.00 $215.00 $650.00 $1224.00 $4296.00 $7818.00 | 8 | |
ALK5 Inhibitor II is a chemical inhibitor that targets ALK5, thereby inhibiting the TGF-β type I receptor. Its action on ALK5 disrupts the phosphorylation events crucial for the activation of the TGF-β signaling pathway, which may indirectly impact Smad8 activity. | ||||||
GW788388 | 452342-67-5 | sc-363544 sc-363544A | 5 mg 25 mg | $95.00 $384.00 | ||
GW788388 is a potent and selective inhibitor of ALK5. Its primary target is the TGF-β type I receptor, and its inhibition disrupts the phosphorylation and activation of ALK5. This interference with the canonical TGF-β signaling pathway can potentially influence Smad8 activity indirectly. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $86.00 | 3 | |
TGF-β RI Kinase Inhibitor V is a small molecule inhibitor that targets the TGF-β type I receptor, ALK5. Its inhibitory action on ALK5 disrupts the activation of the canonical TGF-β signaling pathway, potentially modulating Smad8 activity indirectly. | ||||||
TGF-β RI Kinase Inhibitor VIII | 356559-20-1 | sc-203295 | 2 mg | $100.00 | 2 | |
TGF-β RI Kinase Inhibitor VIII is a potent and selective inhibitor of the TGF-β type I receptor, ALK5. Similar to other ALK5 inhibitors, SB525334 interferes with the phosphorylation and activation of ALK5, disrupting the canonical TGF-β signaling pathway. | ||||||
IN-1130 | 868612-83-3 | sc-507462 | 25 mg | $435.00 | ||
IN-1130 is a chemical compound that selectively inhibits ALK5, the TGF-β type I receptor. Through its action on ALK5, IN-1130 disrupts the canonical TGF-β signaling pathway, potentially influencing Smad8 activity indirectly. | ||||||
SB-505124 | 694433-59-5 | sc-362794 sc-362794A | 10 mg 50 mg | $321.00 $1350.00 | 2 | |
SB505124 is a selective inhibitor of ALK4, a type I receptor in the TGF-β family. While it primarily targets ALK4, the inhibition of this receptor can have downstream effects on Smad8 signaling indirectly. | ||||||
LDN-214117 | 1627503-67-6 | sc-507451 | 5 mg | $165.00 | ||
LDN-214117 is a small molecule inhibitor that selectively targets ALK2, another type I receptor in the TGF-β family. Its inhibition of ALK2 disrupts the canonical TGF-β signaling pathway, potentially impacting Smad8 activity indirectly. | ||||||